WHO Drug Information Vol. 19, No. 2, 2005: ATC/DDD classification: Final list

WHO Drug Information Vol. 19, No. 2, 2005
(2005; 98 pages)

Table of Contents

Biomedicines Update
	International nomenclature and gene therapy products
Safety and Efficacy Issues
	Tiagabine: seizures in patients without a history of epilepsy
	Effect of medroxyprogesterone on bone mineral density
	Tumour necrosis factor inhibitors: safety update
	Pimecrolimus and tacrolimus linked to cancer increase
	Erythropoietin: caution in cancer patients
	Oxcarbazepine: multi-organ hypersensitivity
	Drotrecogin alfa: single organ dysfunction
	Drotrecogin alfa: not indicated for paediatric sepsis
	Interferon beta-1 a and hepatic injury
	Avascular necrosis with interferon alfa-2b in chronic myelogenous leukaemia
	Hylan G-F 20: joint inflammation and pain
	Galantamine and vascular events
	Rosuvastatin: revised start doses
	New kidney function test a better predictor of risk
	Statins and peripheral neuropathy
	Angioedema: still a problem with ACE inhibitors
	More advice on SSRI use
	Million Women Study: latest HRT data
	Tuberculin purified protein derivative (Mantoux) and serious allergic reactions
	Ezetimibe: hepatic, muscle, and pancreatic reactions
	Mefloquine: revised patient information
	Atomoxatine and liver injury
	Gefitinib: failure to show survival in lung cancer
Regulatory Action and News
	Progress on defining borderline pharmaceutical products
	Temozolomide approved for glioblastoma multiforme
	Pramlintide approved for diabetes
	Entecavir approved for chronic hepatitis B
	DNA-based test approved to detect cystic fibrosis
	Nataluzimab: marketing withdrawal pending evaluation
	Rosiglitazone (Nyracta®): voluntary withdrawal
	Risk management legislation
	New pharmacogenomics guidance
Current Topics
	WHO clinical trial registration initiative
	International registration of trial information: Ottawa statement
	Disclosure of information on clinical trials
	Forecasting antiretroviral and diagnostic needs
ATC/DDD classification
	Temporary list
	Final list
Recent Publications and Sources of Information
	Sources and prices of malaria medicines and products
	Launch of a searchable online database of adverse reactions
	Newly-published European Union guidelines
The International Pharmacopoeia
	Monographs for antiretrovirals
		Lamivudine (first draft)
		Nelfinavir mesilate oral powder (first draft)
		Nelfinavir mesilate tablets (first draft)
		Saquinavir mesilate capsules (first draft)
		Stavudine (first draft)
		Zidovudine (first draft)
International Nonproprietary Names for Pharmaceutical Substances (INN)

Final list

The following anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed by the WHO International Working Group for Drug Statistics Methodology in October 2004. They came into force on 1 March 2005 and will be included in the January 2006 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy. The WHO Collaborating Centre for Drug Statistics Methodology can be contacted through e-mail: whocc@nmd.no.

ATC level	INN/Common name	ATC code
*New ATC level codes (other than 5th level):*
	Other anti-parathyroid agents	H05BX
*New ATC 5th level codes:*
	abetimus	L04AA22
	acetyl dihydrocodeine	R05DA12
	alglucosidase alfa	A16AB07
	anidulafungin	J02AX06
	atazanavir	J05AE08
	brivudine	J05AB15
	cefditoren	J01DD16
	ceforanide	J01DC11
	cinacalcet	H05BX01
	dimethoxanate	R05DB28
	duloxetine	N06AX21
	erlotinib	L01XX34
	fenetylline	N06BA10
	gadoxetic acid	V08CA10
	fatifloxacin	S01AX21
	histamine dihydrochloride	L03AX14
	ibritumomab tiuxetan [90Y]	V10XX02
	iodoform	D09AA13
	ivabradine	C01EB17
	measles, combinations with mumps, rubella and varicella, live attenuated	J07BD54
	natalizumab	L04AA23
	pregabalin	N03AX16
	prulifloxacin	J01MA17
	risedronic acid and calcium	M05BB02
	roflumilast	R03DX07
	spiramycin, combinations with
	other antibacterials	J01RA04
	sulfamerazine	D06BA06
	sulfanilamide	D06BA05
	treprostinil	B01AC21

ATC name changes

Previous	New	ATC code
histamine	histamine phosphate	V04CG03
anti-parathyroid hormones	Anti-parathyroid agents	H05B

New DDDs:

INN/common name	DDD	Unit	Adm.R	ATC code
atazanavir	0.3	g	O	J05AE08
azithromycin	0.5	g	P	J01FA10
brivudine	0.125	g	O	J05AB15
ceforanide	4	g	P	J01DC11
emtricitabine	0.2	g	O	J05AF09
esomeprazole	30	mg	P	A02BC05
fosamprenavir	1.4	g	O	J05AE07
iloprost	0.15	mg	inhal	B01AC11
levodopa, decarboxylase inhibitor and COMT-inhibitor	0.45	g*	O	N04BA03
melagatran	6	mg	P	B01AE04
moxifloxacin	0.4	g	P	J01MA14
nicotine	30	mg	SL	N07BA01
omalizumab	16	mg	P	R03DX05
oxybutynin	3.9	mg	TD	G04BD04
pregabalin	0.3	g	O	N03AX16
trospium	40	mg	O	G04BD09
ximelagatran	48	mg	O	B01AE05
zonisamide	0.2	g	O	N03AX15

* as levodopa